PXD021819

PXD021819 is an original dataset announced via ProteomeXchange.

Title	Discovery and pharmacological evaluation of STEAP4 as a novel target for HER2 overexpressing Breast cancer
Description	The HER2 overexpressing and the Triple Negative Breast Cancer forms (TNBC) remain the most aggressive subtypes of BC with poor prognosis, frequent disease relapse and metastasis. In this study the aim was to identify key membrane-associated proteins which are overexpressed in these aggressive BC subtypes and can serve as potential biomarkers or drug targets. We leveraged on the development of a membrane enrichment protocol in combination with the global profiling GeLC-MS/MS technique, and compared the proteomic profiles of a HER2 overexpressing (HCC-1954) and a TNBC (MDA-MB-231) cell line with that of a benign control breast cell line (MCF-10A). An average of 2300 proteins were identified from each cell line, of which approximately 600 were membrane-associated proteins. Our global proteomic methodology in tandem with invigoration by Western blot and Immunofluorescence analysis, readily detected several previously-established BC receptors like HER2 and EPHA2, but importantly STEAP4 and CD97 emerged as novel potential candidate markers.
HostingRepository	PRIDE
AnnounceDate	2023-11-14
AnnouncementXML	Submission_2023-11-14_07:37:35.120.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Konstantinos Vougas
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iodoacetamide derivatized residue
Instrument	LTQ Orbitrap Elite

Revision	Datetime	Status	ChangeLog Entry
0	2020-10-05 03:50:37	ID requested
1	2023-03-10 15:07:10	announced
⏵ 2	2023-11-14 07:37:38	announced	2023-11-14: Updated project metadata.

Orfanou IM, Argyros O, Papapetropoulos A, Tseleni-Balafouta S, Vougas K, Tamvakopoulos C, Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer. Front Oncol, 11():608201(2021) [pubmed]

submitter keyword: Breast Cacner, therapeutic targets, human, STEAP4, orbitrap, HER2

Constantin Tamvakopoulos
contact affiliation	Division of Pharmacology‐Pharmacotechnology, Biomedical Research Foundation, Academy of Athens (BRFAA).
contact email	ctamvakop@bioacademy.gr
lab head
Konstantinos Vougas
contact affiliation	Biotechnology
contact email	kvougas@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/03/PXD021819

PRIDE project URI

• PRIDE
  1. PXD021819
     1. Label: PRIDE project
     2. Name: Discovery and pharmacological evaluation of STEAP4 as a novel target for HER2 overexpressing Breast cancer